AquaBounty: FDA could approve biotech salmon this year

04/24/2013 | Hartford Courant (Conn.), The

AquaBounty Technologies expects its biotech salmon, which grows twice as fast as traditional salmon, to be approved by the FDA before the year ends. "There have been no new legal issues, no new regulatory issues, no new environmental issues raised," CEO Ronald Stotish said at the BIO International Convention. The public comment period ends on Friday, and the FDA's decision could come 150 to 180 days later, Stotish said.

View Full Article in:

Hartford Courant (Conn.), The

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Eastern Zone Sales Director
Regenesis Biomedical
Multiple Locations, SL_Multiple Locations
Director, Compliance - Health Plan Privacy & Security
Kaiser Permanente
Oakland, CA
Regulatory Counsel
Food and Drug Administration
Silver Spring, MD
Pharmacy Care Manager
National Association of Chain Drug Stores
Arlington, VA
Vice President, Commercial Markets
Meridian Health
Neptune, NJ